<?xml version="1.0" encoding="utf-8" standalone="no"?>
<billStatus>
  <version>3.0.0</version>
  <bill>
    <number>585</number>
    <updateDate>2023-01-11T13:47:48Z</updateDate>
    <updateDateIncludingText>2023-01-11T13:47:48Z</updateDateIncludingText>
    <originChamber>Senate</originChamber>
    <type>S</type>
    <introducedDate>2021-03-03</introducedDate>
    <congress>117</congress>
    <committees>
      <item>
        <systemCode>sscm00</systemCode>
        <name>Commerce, Science, and Transportation Committee</name>
        <chamber>Senate</chamber>
        <type>Standing</type>
        <activities>
          <item>
            <name>Referred to</name>
            <date>2021-03-03T23:05:48Z</date>
          </item>
        </activities>
      </item>
    </committees>
    <relatedBills>
      <item>
        <title>United States Anti-Doping Agency Reauthorization Act of 2021</title>
        <congress>117</congress>
        <number>172</number>
        <type>HR</type>
        <latestAction>
          <actionDate>2021-04-15</actionDate>
          <text>Received in the Senate and Read twice and referred to the Committee on Commerce, Science, and Transportation.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Identical bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
    </relatedBills>
    <actions>
      <item>
        <actionDate>2021-03-03</actionDate>
        <committees>
          <item>
            <systemCode>sscm00</systemCode>
            <name>Commerce, Science, and Transportation Committee</name>
          </item>
        </committees>
        <sourceSystem>
          <name>Senate</name>
        </sourceSystem>
        <text>Read twice and referred to the Committee on Commerce, Science, and Transportation.</text>
        <type>IntroReferral</type>
      </item>
      <item>
        <actionDate>2021-03-03</actionDate>
        <text>Introduced in Senate</text>
        <type>IntroReferral</type>
        <actionCode>10000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
    </actions>
    <sponsors>
      <item>
        <bioguideId>M000934</bioguideId>
        <fullName>Sen. Moran, Jerry [R-KS]</fullName>
        <firstName>Jerry</firstName>
        <lastName>Moran</lastName>
        <party>R</party>
        <state>KS</state>
        <isByRequest>N</isByRequest>
      </item>
    </sponsors>
    <cosponsors>
      <item>
        <bioguideId>B001277</bioguideId>
        <fullName>Sen. Blumenthal, Richard [D-CT]</fullName>
        <firstName>Richard</firstName>
        <lastName>Blumenthal</lastName>
        <party>D</party>
        <state>CT</state>
        <sponsorshipDate>2021-03-03</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
    </cosponsors>
    <policyArea>
      <name>Sports and Recreation</name>
    </policyArea>
    <subjects>
      <legislativeSubjects>
        <item>
          <name>Alternative dispute resolution, mediation, arbitration</name>
        </item>
        <item>
          <name>Athletes</name>
        </item>
        <item>
          <name>Child health</name>
        </item>
        <item>
          <name>Congressional oversight</name>
        </item>
        <item>
          <name>Criminal investigation, prosecution, interrogation</name>
        </item>
        <item>
          <name>Drug safety, medical device, and laboratory regulation</name>
        </item>
        <item>
          <name>Drug, alcohol, tobacco use</name>
        </item>
        <item>
          <name>Due process and equal protection</name>
        </item>
        <item>
          <name>International law and treaties</name>
        </item>
        <item>
          <name>International organizations and cooperation</name>
        </item>
        <item>
          <name>Medical tests and diagnostic methods</name>
        </item>
        <item>
          <name>Olympic games</name>
        </item>
      </legislativeSubjects>
      <policyArea>
        <name>Sports and Recreation</name>
      </policyArea>
    </subjects>
    <summaries>
      <summary>
        <versionCode>00</versionCode>
        <actionDate>2021-03-03</actionDate>
        <actionDesc>Introduced in Senate</actionDesc>
        <updateDate>2021-04-13T21:04:20Z</updateDate>
        <text><![CDATA[ <p><strong>United States Anti-Doping Agency Reauthorization Act of 2021</strong></p> <p>This bill authorizes appropriations for the U.S. Anti-Doping Agency (USADA) through FY2030.</p> <p>The bill adds requirements that USADA</p> <ul> <li>be responsible for certifying in advance any testing conducted by international organizations under the World Anti-Doping Code for international amateur athletes and athletic competitions occurring within the jurisdiction of the United States; and</li> <li> promote a positive youth sport experience by using a portion of its funding to provide educational materials on sportsmanship, character building, and healthy performance for those participating in youth sports.</li> </ul> <p>The bill requires any action taken by USADA to enforce a policy, procedure, or requirement against a person with respect to a violation of federal law, including an investigation, disciplinary action, sanction, or any other administrative action, to be carried out in a manner that provides due process protection.</p> <p>The Department of Justice, the Department of Homeland Security, and the Food and Drug Administration&nbsp;must provide to USADA information relating to the prevention of the use of performance-enhancing drugs or the prohibition of performance-enhancing methods.</p>]]></text>
      </summary>
    </summaries>
    <title>United States Anti-Doping Agency Reauthorization Act of 2021</title>
    <titles>
      <item>
        <titleType>Display Title</titleType>
        <title>United States Anti-Doping Agency Reauthorization Act of 2021</title>
      </item>
      <item>
        <titleType>Official Title as Introduced</titleType>
        <title>A bill to reauthorize the United States Anti-Doping Agency, and for other purposes.</title>
        <billTextVersionName>Introduced in Senate</billTextVersionName>
        <billTextVersionCode>IS</billTextVersionCode>
      </item>
      <item>
        <titleType>Short Title(s) as Introduced</titleType>
        <title>United States Anti-Doping Agency Reauthorization Act of 2021</title>
        <billTextVersionName>Introduced in Senate</billTextVersionName>
        <billTextVersionCode>IS</billTextVersionCode>
      </item>
    </titles>
    <textVersions>
      <item>
        <type>Introduced in Senate</type>
        <date>2021-03-03T05:00:00Z</date>
        <formats>
          <item>
            <url>https://www.govinfo.gov/content/pkg/BILLS-117s585is/xml/BILLS-117s585is.xml</url>
          </item>
        </formats>
      </item>
    </textVersions>
    <latestAction>
      <actionDate>2021-03-03</actionDate>
      <text>Read twice and referred to the Committee on Commerce, Science, and Transportation.</text>
    </latestAction>
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>
